Tamam Cüneyt, Tamam Müge
Department of Orthopedics and Traumatology, Specialist Private Practice, İstanbul, Turkey.
Eklem Hastalik Cerrahisi. 2018 Dec;29(3):184-8. doi: 10.5606/ehc.2018.60419.
This study aims to evaluate the prognostic significance of maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) for bone sarcoma.
We retrospectively evaluated 34 patients (24 males, 10 females; mean age 36.6±24.2 years; range, 5 to 77 years) with pathologically proven bone sarcoma who underwent 18FDG-PET/CT for initial staging between September 2013 and September 2017. SUVmax of primary lesions were measured. Cumulative survival rate was calculated to evaluate the prognostic value of 18FDG-PET/CT findings. Survival duration was defined as the elapsed duration from the date of pre-treatment 18FDG-PET/CT scanning until the date of the final examination before the date of death.
The cut-off value for SUVmax in the definition of progression was 8. Mean SUVmax of the progressive group was statistically significantly higher than the non-progressive group. Distant metastases were present in 14 (41.1%) cases. Mortality and cumulative survival rates were 14.7% and 79.1±0.08%, respectively.
Semiquantitative estimation of primary tumor metabolic activity in terms of baseline SUVmax using 18FDG-PET/CT can predict the overall survival of patients with bone sarcoma.
本研究旨在评估18F-氟-2-脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18FDG-PET/CT)中最大标准化摄取值(SUVmax)对骨肉瘤的预后意义。
我们回顾性评估了2013年9月至2017年9月期间34例经病理证实的骨肉瘤患者(24例男性,10例女性;平均年龄36.6±24.2岁;范围5至77岁),这些患者因初始分期接受了18FDG-PET/CT检查。测量了原发灶的SUVmax。计算累积生存率以评估18FDG-PET/CT检查结果的预后价值。生存时间定义为从治疗前18FDG-PET/CT扫描日期到死亡日期前最后一次检查日期的 elapsed duration。
进展定义中SUVmax的临界值为8。进展组的平均SUVmax在统计学上显著高于非进展组。14例(41.1%)出现远处转移。死亡率和累积生存率分别为14.7%和79.1±0.08%。
使用18FDG-PET/CT根据基线SUVmax对原发肿瘤代谢活性进行半定量评估可预测骨肉瘤患者的总生存期。